Conference
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).
Authors
Fleming MT; Pond GR; Armstrong AJ; Wood BA; Brookes M; Leopold LH; Matveev VB; Burke JM; Caton JR; Sonpavde G
Volume
29
Pagination
pp. e15019-e15019
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.e15019
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X